| Notice |
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hy
alteogen
|
2024.11.14
|
Votes 0
|
Views 1022
|
alteogen |
2024.11.14 |
| Notice |
Alteogen announces amendment to license agreement with MSD.
alteogen
|
2024.02.24
|
Votes 0
|
Views 4386
|
alteogen |
2024.02.24 |
| Notice |
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
alteogen
|
2023.09.06
|
Votes 0
|
Views 4295
|
alteogen |
2023.09.06 |
| Notice |
Hyaluronidase : A new way to be excluded from drug price negotiations under IRA
alteogen
|
2023.08.01
|
Votes 0
|
Views 4265
|
alteogen |
2023.08.01 |
| Notice |
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 6355
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
alteogen
|
2023.01.06
|
Votes 0
|
Views 4444
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 4115
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme™ Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 4220
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 3977
|
alteogen |
2023.01.06 |
| 29 |
Merck to Manufacture Next-Generation Biotherapeutics for Alteogen
alteogen
|
2023.01.06
|
Votes 0
|
Views 4065
|
alteogen |
2023.01.06 |
| 28 |
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
alteogen
|
2023.01.06
|
Votes 0
|
Views 2801
|
alteogen |
2023.01.06 |
| 27 |
Alteogen Inc. obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
alteogen
|
2019.05.22
|
Votes 0
|
Views 6338
|
alteogen |
2019.05.22 |
| 26 |
Alteogen applies for P1 trial for Eylea biosimilar
alteogen
|
2019.02.28
|
Votes 0
|
Views 4909
|
alteogen |
2019.02.28 |
| 25 |
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen
|
2019.01.04
|
Votes 0
|
Views 5125
|
alteogen |
2019.01.04 |
| 24 |
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen
|
2018.12.04
|
Votes 0
|
Views 5155
|
alteogen |
2018.12.04 |
| 23 |
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen
|
2018.08.17
|
Votes 0
|
Views 4861
|
alteogen |
2018.08.17 |
| 22 |
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen
|
2018.08.07
|
Votes 0
|
Views 7956
|
alteogen |
2018.08.07 |
| 21 |
Alteogen develops antibody transferring IV to SC injection
alteogen
|
2018.07.30
|
Votes 0
|
Views 7520
|
alteogen |
2018.07.30 |
| 20 |
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen
|
2018.07.11
|
Votes 0
|
Views 3962
|
alteogen |
2018.07.11 |
